Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

Company Overview - BioCryst Pharmaceuticals (BCRX) is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year change of +20.8% [2] - Revenues are anticipated to be $98.27 million, which is a 19.1% increase from the same quarter last year [2] - The Most Accurate Estimate for BioCryst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.62% [5] Earnings Expectations - The upcoming earnings report is scheduled for August 5, and the stock price may react positively if actual results exceed expectations [1] - Conversely, if the results fall short, the stock may decline [1] - The consensus EPS estimate has been revised 2.7% lower over the last 30 days, indicating a reassessment by analysts [2] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.23 per share but actually reported a loss of $0.17, resulting in a surprise of +26.09% [7] - Over the past four quarters, BioCryst has beaten consensus EPS estimates three times [7] Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to post a loss of $0.10 per share, indicating a year-over-year change of -25% [9] - Ardelyx's revenue is projected to be $55.73 million, up 149.6% from the previous year [9] - The consensus EPS estimate for Ardelyx has been revised 14% higher in the last 30 days, resulting in a positive Earnings ESP of 3.92% [9]